← Leaderboards
Yukari Perrella
Yuma Therapeutics Corporation
$643,948
Attributed
$1,674,336
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $958.6K · FY2012–15$1M$750K$500K$250K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$1,674,336 · 2
By mechanism
R42$1,473,584 · 1
R41$200,752 · 1
Top collaborators
- Marcie A Glicksman2 shared
- Kevin Hodgetts2 shared
- Gregory D Cuny1 shared
Most similar at Yuma Therapeutics Corporation
Same institution · by research overlap
- Kevin Hodgetts$12,783,151
Others in their field
Top investigators on “Molecular Chaperones”
- Scott J Hultgren · Washington University$24,111,975
- Judith Frydman · Stanford University$23,842,034
- Wah Chiu · Baylor College Of Medicine$22,055,847
- Randal J. Kaufman · Indiana University Indianapolis$21,677,694
- Richard I. Morimoto · Northwestern University$18,534,805
- William Tobey Wickner · Dartmouth College$17,981,123
Research focus
Molecular ChaperonesNovel StrategiesInhibitor/AntagonistMild Cognitive ImpairmentNerve DegenerationNeuronsHeat-Shock Proteins 90Hsp 90 InhibitionCerebrospinal FluidIn VivoDisease ProgressionDoseNeurodegenerative DisordersNeurofibrillary TanglesAbnormally Phosphorylated TauDepositionAlzheimer&AposBrain TissueAffectBiochemicalCyclin-Dependent KinasesIn VitroBrainPathway Interactions
Grant awards (3)
Brain penetrant Hsp90 inhibitors for Alzheimer's disease$515,014
R42 · FY2015 · AG · contact PI
Brain penetrant Hsp90 inhibitors for Alzheimer's disease$958,570
R42 · FY2014 · AG · contact PI
CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease$200,752
R41 · FY2012 · AG · contact PI